Price Crosses Moving Average
|Bid||141.43 x 800|
|Ask||141.50 x 800|
|Day's Range||140.82 - 145.39|
|52 Week Range||109.16 - 154.50|
|Beta (5Y Monthly)||0.66|
|PE Ratio (TTM)||25.14|
|Earnings Date||Apr 13, 2020|
|Forward Dividend & Yield||3.80 (2.76%)|
|Ex-Dividend Date||Feb 23, 2020|
|1y Target Est||156.18|
Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.
ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?
We don't invest in "the stock market" as a whole because we know how easily a few truly weak spots can mask strength elsewhere, asserts Hilary Kramer, editor of GameChangers.
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The U.S. reached a grim milestone on Monday, passing 10,000 coronavirus-related deaths, and according to a prominent physician, the nation won’t move beyond the crisis without a vaccine.
Seemingly hopeful news came out of New York Monday, which could be nearing its apex of the novel coronavirus crisis, while markets opened higher to start a week that could see other metro areas surge in cases and deaths.
Jim Cramer said on "Mad Money Lightning Round" he is a buyer of Alteryx Inc (NYSE: AYX) because it has a great growth.Instead of InVitae Corp (NYSE: NVTA), Cramer would rather buy Johnson & Johnson (NYSE: JNJ). He finds InVitae very dicey.Cramer would stay away from Delta Air Lines, Inc. (NYSE: DAL). He is concerned the airlines are going to get diluted when they take money from the government.Alteryx, Okta Inc (NASDAQ: OKTA) and Constellation Brands, Inc. (NYSE: STZ) are better picks than Realty Income Corp (NYSE: O) for a 24-year-old investor. Cramer thinks young people should be looking for growth.Upwork Inc (NASDAQ: UPWK) is an interesting idea, said Cramer. He needs some time to do a research on this stock.Cramer is willing to bless Switch Inc (NYSE: SWCH) as a buy, because the data center is hotter than it has ever been as people are working from home.Nokia Oyj (NYSE: NOK) is not good enough, thinks Cramer.See more from Benzinga * Berkshire Hathaway Reduces Position In Delta Air Lines, Southwest Airlines * Mike Khouw's Dollar General Trade * 'Fast Money' Traders Weigh In On AT&T, Tesla And Twitter(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Almost three months have passed since COVID-19 began its spread beyond China’s borders, and the market remains in free fall. Capping off another volatile week, stocks fell on Friday April 3 in response to disappointing U.S. economic data, offsetting gains posted in the previous session. Based on a new report from the Labor Department, the U.S. economy saw 701,000 jobs erased in March, much more than economists originally expected as the figure doesn’t even include the 10 million unemployment filings that occurred after March 14. In addition, New York Governor Andrew Cuomo announced on Friday that the state had experienced the biggest jump in COVID-19-related deaths the day before, sending the market plummeting even further. For those investors feeling hopeless right now, there’s a bright spot on the horizon. Several companies have stepped up to the plate, developing innovative solutions to fight off the deadly virus. According to some Wall Street pros, these new technologies represent a possible inflection point in the war against COVID-19, and could even help drive the stock market’s recovery. Taking all of this into consideration, we used TipRanks’ database to get more information on three stocks at the frontline of the COVID-19 battle. The investing platform revealed that all of these Buy-rated tickers have been flagged by some analysts for their technology’s huge potential. Let’s get started. Abbott Laboratories (ABT) In the fight against COVID-19, Abbott’s tests to identify the virus have helped healthcare providers make significant headway. Along with its molecular test that is already being used in labs throughout the U.S., the company revealed on April 3 that the FDA granted emergency use authorization (EUA) for a rapid coronavirus testing system. As the product can detect positive results in five minutes and negative results in 13 minutes, much faster than any other available COVID-19 tests, Wall Street focus has locked in on ABT. Weighing in for Barclays, analyst Kristen Stewart believes the test will be performed on the ID NOW platform, an isothermal nucleic acid amplification technology, and thus offers advantages that go beyond its speed. “The system is easy to use with minimal training. The tests are CLIA waived, which is an advantage and allows for the placement in physician offices and urgent care offices. We estimate there are at least 15,000 systems in the United States, placed throughout physician offices, urgent care offices, and other healthcare facilities,” Stewart explained. As for the total opportunity, Stewart doesn’t dispute that Abbott’s manufacturing capacity, which she thinks would be the rate limiting factor as there is significant demand for the test, remains unclear. “The pricing would likely be under the non-CDC pricing ~$51 level, perhaps in the $35-$45 range. We hope Abbott would supply these details when it announces approval,” the analyst noted. That being said, 4 million of its molecular tests can be conducted each month on its m2000 systems, with ABT charging about $30 per test. As a result, Stewart kept an Overweight call and $98 price target on the stock. Should this target be met, a twelve-month gain of 23% could be in the cards. (To watch Stewart’s track record, click here) Turning now to other Wall Street analysts, the bulls have it. With 8 Buy ratings and 3 Holds assigned in the last three months, the consensus rating comes in as a Moderate Buy. The $97.89 average price target implies only slightly less upside potential than Stewart’s forecast. (See Abbott stock analysis on TipRanks)Johnson & Johnson (JNJ) Next up is a consumer goods and healthcare heavyweight, Johnson & Johnson, which is developing a vaccine against COVID-19. After the company identified a lead candidate, one analyst thinks JNJ is one of the names capable of fueling the stock market’s turnaround. With a lead experimental vaccine candidate selected, Kristen Stewart, who also covers ABT, points out that at the latest, JNJ can kick off Phase 1 human clinical studies by September 2020. According to management, the first doses of the vaccine could be available under Emergency Use Authorization (EUA) in early 2021. Adding to the good news, JNJ has significantly expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA), with both entities pledging more than $1 billion to co-fund the vaccine’s development and clinical testing. If that wasn’t enough, Stewart notes “BARDA and JNJ have provided additional funding to allow expansion of ongoing work to identify anti-viral treatments against COVID-19.” However, while JNJ has ramped up the scaling of manufacturing capacity and has a target of supplying more than 1 billion vaccine doses, there is a risk that the candidate won’t eventually receive approval. Having said that, Stewart argues the real goal is to develop an affordable vaccine “on a not-for-profit basis for emergency pandemic use.” She added, “Thus we would anticipate the cost it would charge for the vaccine would recoup the cost of development, cost of scaling up the manufacturing, and cost of production. Thus, we would not look at the vaccine as being a windfall or major positive from a financial perspective. We believe J&J is doing the right thing and adhering to the company’s long-running Credo.” Despite the fact that its medical device business could take a hit as elective procedures are delayed, its COVID-19 vaccine candidate, balanced portfolio, strong balance sheet and dividend, yielding 2.8% and paying out $3.80 per share annually, reaffirm Stewart’s confidence. Bearing this in mind, she maintained a Buy rating and $173 price target. This implies shares could surge 29% in the next year. What does the rest of the Street have to say? Out of 9 recent reviews, 8 were bullish, making the consensus rating a Strong Buy. In addition, the $157.22 average price target brings the upside potential to 17%. (See Johnson & Johnson stock analysis on TipRanks) Gilead Sciences (GILD) Biotech Gilead Sciences has grabbed headlines left and right thanks to its experimental COVID-19 treatment, remdesivir. With the company now stating it will donate 1.5 million doses of the drug, which could treat 140,000 patients, it’s no wonder some analysts are standing firmly behind GILD. Shares are up 20% year-to-date, but Jeffries’ Michael Yee believes its growth story is still heating up. Looking at the big picture, he argues, “GILD remains a defensive positioning stock particularly in this macro environment. We appreciate short-term trading has been mostly dictated around market volatility risk-on/off and expectations on remdesivir for COVID-19 data starting in April.” That being said, there’s more to this biotech’s “improving story”. The company has placed a significant focus on expansion, with its recent M&A activity including a $5 billion deal with immuno-oncology company Forty Seven. Additionally, its second quarter Phase 3 filgotinib UC data readout could send shares on an upward trajectory as well as improve sentiment surrounding the drug’s differentiation from AbbVie. Yee already thinks that the pbo-adjusted remission rates imply that filgotinib is “competitive with other UC drugs.” Expounding on this, he stated, “While we expect investors to make cross-trial comparisons, we caution comparing directly to other UC datasets is imprecise due to differing baseline characteristics such as proportion of biologic naive/experienced and slightly different endpoints of the Mayo score. However -- recent commentary from GILD suggests positive confidence around results and good activity in both biologic naive and experienced.” With an August PDUFA date for filgotinib in RA, Yee does, however, acknowledge that a class label Black Box could be given as a result of uncertainty related to degree of bleeding difference between various JAK drugs. It’s also still unclear if filgotinib will be approved at the 200mg dose. Commenting on the second issue, Yee said, “In any case, it's reasonable to approve 200mg particularly if the MANTA interim look is OK but FDA is a conservative bunch. Also, even if not, we point out ABBV was only approved at the low dose in RA as well so it would not be a totally critical issue.” To this end, Yee reiterated a Buy recommendation and $89 price target, indicating 14% upside potential. (To watch Yee’s track record, click here) Looking at the consensus breakdown, 10 Buys, 9 Holds and 2 Sells add up to a Moderate Buy consensus rating. At $76.88, the average price target puts the downside potential at 2%. (See Gilead stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
As the coronavirus pandemiccurtails economic activity around the world and financial markets teeter, investors have been scrambling for cash. That includes gravitating toward companies with strong balance sheets—a cohort that has shrunk over the past decade as debt held by nonfinancial corporations ballooned 76%, to $6.6 trillion. Companies with strong balance sheets have outperformed the broader market since the S&P 500 peaked in mid-February, according to Goldman Sachs chief U.S. equity strategist David Kostin. Widespread economic distress is likely to prompt even more companies to re-evaluate their dependence on debt financing in coming months—low interest rates notwithstanding—and look to shockproof their finances by piling up more cash.
New and necessary government mandates to combat the spread of coronavirus and the COVID-19 illness it causes are producing unprecedented challenges for investors. This time the negative impact is indiscriminate — impaired business activity and enforced quarantines are producing negative consequences for both strong and weak companies. Alongside the acceleration of market volatility, we have been conducting extreme stress-testing on all of our holdings for heavy pressure on revenue, profit, and cash flow, going beyond the usual EBITDA and leverage metrics.
Shares of Fate Therapeutics popped Friday after the biotech company announced a deal with Johnson & Johnson to develop cancer treatments in the immuno-oncology class of medicine.
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
Johnson & Johnson stock is under pressure amid the coronavirus correction. Further, it's facing litigation tied to opioids and talcum powder. Is now the time to invest in JNJ stock?
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) * BIOLASE Inc (NASDAQ: BIOL) * BioNano Genomics Inc (NASDAQ: BNGO) (priced $18 million common stock and warrant offering) * Celcuity Inc (NASDAQ: CELC) * China SXT Pharmaceuticals Inc (NASDAQ: SXTC) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * ENDRA Life Sciences Inc (NASDAQ: NDRA) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Mediwound Ltd (NASDAQ: MDWD) * Merus NV (NASDAQ: MRUS) * Myokardia Inc (NASDAQ: MYOK) * Neovasc Inc (NASDAQ: NVCN) * Opko Health Inc. (NASDAQ: OPK) * PDS Biotechnology Corp (NASDAQ: PDSB) * Phio Pharmaceuticals Corp (NASDAQ: PHIO) * Precipio Inc (NASDAQ: PRPO) * Seelos Therapeutics Inc (NASDAQ: SEEL) * Sellas Life Sciences Group Inc (NASDAQ: SLS) * Chanticleer Holdings Common Stock (NASDAQ: SONN) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ)'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.Janssen will contribute proprietary antigen-binding domains for up to four tumor-associated antigen targets, and pay Fate $50 million in cash and also subscribe to $50 million in the latter's common shares at $31 per share.Fate will be responsible for developing candidate until IND filing after which Janssen has the right to exercise options to license these.Fate is eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.Fate shares jumped 23.40% to $26 in after-hours trading.Sanofi, Regeneron Announces Positive Latestage Data For Dupixent-SoC Combo In Eczema In Kids Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced data from pivotal Phase 3 study of Dupixent combined with standard-of-care topical corticosteroidsin children aged 6-11 years with uncontrolled severe atopic dermatitis, which showed significantly improved disease signs, symptoms and health-related quality of life.The company said detailed results will be presented during a session at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference on Sunday.See Also: Attention Biotech Investors: Mark Your Calendar For These April PDUFA DatesNovartis, Incyte to Study Ruxolitinib For COVID-19 Related Cytokine Storm Novartis AG (NYSE: NVS) said it a plans to initiate a Phase 3 clinical trial in collaboration with Incyte Corporation (NASDAQ: INCY) to evaluate the use of ruxolitinib for the treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.Novartis said it is taking steps to manage the anticipated increase in COVID-19 related requests for Jakavi - trade name of ruxolitinib in territories outside of the U.S. - without interrupting access for patients taking the drug for its licensed indications.Novartis has licensed Jakavi from Incyte to commercialize in regions outside of the U.S., while Incyte markets it in the U.S. under the name Jakafi.Novartis shares gained 1.18% to $84.59 in after-hours trading, while Incyte stock rose 1% to 1.86% to $78.50 in after-hours trading.Immucell Pre-announces Q1 Net Product Sales Growth of 11.3% ImmuCell Corporation (NASDAQ: ICCC) announced preliminary first-quarter results, expecting product sales of $4.9 million, up 11.3% year-over-year.Savara Licenses Latestage Inhaled Antibiotic Asset From Grifols Savara Inc (NASDAQ: SVRA) said it has entered into an exclusive license and collaboration agreement with Grifols SA - ADR ADR Class B (NASDAQ: GRFS) for Apulmiq - inhaled liposomal ciprofloxacin. Apulmiq is a late-stage investigational inhaled antibiotic in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis.The agreement provides for Savara obtaining worldwide rights to develop and commercialize Apulmiq for an upfront payment. if regulatory approval is obtained, Grifols will be eligible for regulatory milestone payments as well as royalties and potential tiered sales milestones upon commercialization.Savara said it expects to work with regulatory agencies to plan a confirmatory Phase 3 study.The stock rallied 11.83% to $2.08 in after-hours trading.Emergent Biosolutions Gets $14.5M Grant For COVID-19 Therapy Development Emergent Biosolutions Inc (NYSE: EBS) said it has entered into a formal partnership with the U.S. government to expedite development of plasma-derived therapy for patients with COVID-19. The company said it has received $14.5 million from the BARDA for its COVID-HIG program - one of the hyperimmune development programs announced by the company in March.Announcements On COVID-related Impacts Updating on COVID-19 impact, Denali Therapeutics Inc (NASDAQ: DNLI), a neurodegenerative diseases-focused biopharma, said it does not expect delays to its clinical trials due to manufacturing or supply-chain issues. The company, however, said it has paused enrollment of new patients into some of its trials.The company also said it has sufficient cash to fund business operations through 2022.The stock slipped 2.41% to $17.02 in after-hours trading.Dynavax Technologies Corporation (NASDAQ: DVAX) announced withdrawal of its 2020 guidance, citing uncertainties about the duration and effect of the COVID-19 pandemic and the potential impact on hepatitis B vaccine - Heplisav-B - product sales.The company also said it has already exceeded the Heplisav-B minimum product revenue covenant in its term loan agreement of $30 million for the annual measurement period ending June 30.On The Radar Clinical Readout Prothena Corporation PLC (NASDAQ: PRTA) said its development partner Roche Holdings AG Basel ADR (OTC: RHHBY) will present baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease in an oral presentation at the Advances in Alzheimer's and Parkinson's Therapies AAT-AD/PD Focus Meeting being held virtually.IPO Zentalis Pharma, a biopharma focused on developing small molecule therapeutics targeting fundamental pathways of cancer, said it has priced its initial public offering of 9.18 million shares at $18 per share for raising gross proceeds of $165.2 million. The company expects the offering to close April 7. The shares are to be listed on the Nasdaq under the ticker symbol ZNTL.See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection * The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Since the start of the crisis, Alex Gorsky, Johnson & Johnson chief executive, has started every video call by asking his colleagues to talk about something positive in their lives. With a half billion dollar investment from Mr Gorsky, matched by the same amount from the US government to speed up the process, J&J’s researchers had come up with a drug they believed could be ready for human trials by September. The vaccine, Johnson & Johnson said, would be available on a not-for-profit basis.